RESUMO
Dabrafenib is an inhibitor of BRAF V600E used for treating metastatic melanoma but a majority of patients experience adverse effects. Methods to measure the levels of dabrafenib and major metabolites during treatment are needed to allow development of individualized dosing strategies to reduce the burden of such adverse events. In this study, an LC-MS/MS method capable of measuring dabrafenib quantitatively and six metabolites semi-quantitatively is presented. The method is fully validated with regard to dabrafenib in human plasma in the range 5-5000 ng/mL. The analytes were separated on a C18 column after protein precipitation and detected in positive electrospray ionization mode using a Xevo TQ triple quadrupole mass spectrometer. As no commercial reference standards are available, the calibration curve of dabrafenib was used for semi-quantification of dabrafenib metabolites. Compared to earlier methods the presented method represents a simpler and more cost-effective approach suitable for clinical studies. Graphical abstract Combined multi reaction monitoring transitions of dabrafenib and metabolites in a typical case sample.
Assuntos
Antineoplásicos/sangue , Antineoplásicos/metabolismo , Imidazóis/sangue , Imidazóis/metabolismo , Oximas/sangue , Oximas/metabolismo , Espectrometria de Massas em Tandem/métodos , Cromatografia Líquida de Alta Pressão/economia , Cromatografia Líquida de Alta Pressão/métodos , Monitoramento de Medicamentos/economia , Monitoramento de Medicamentos/métodos , Humanos , Limite de Detecção , Microssomos Hepáticos/metabolismo , Reprodutibilidade dos Testes , Espectrometria de Massas em Tandem/economiaRESUMO
Asoxime (HI-6) is a well known oxime reactivator used for counteracting intoxication by nerve agents. It is able to reactivate acetylcholinesterase (AChE) inhibited even by sarin or soman. The present experiment was aimed to determine markers of oxidative stress represented by thiobarbituric acid reactive substances and antioxidants represented by ferric reducing antioxidant power, reduced and oxidized glutathione in a Beagle dog model. Two groups of dogs were intramuscularly exposed to single (11.4 mg/kg.b.wt.) or tenfold (114 mg/kg.b.wt.) human therapeutically doses of HI-6. HI-6 affinity for AChE in vitro was evaluated in a separate experiment. Complete serum biochemistry and pharmacokinetics were also performed with significant alteration in blood urea nitrogen, creatine phosphokinase, glucose and triglycerides. Blood samples were collected before HI-6 application and after 30, 60, and 120 min. The overall HI-6 impact on organism is discussed.
Assuntos
Reativadores da Colinesterase/administração & dosagem , Estresse Oxidativo , Oximas/administração & dosagem , Compostos de Piridínio/administração & dosagem , Acetilcolinesterase/metabolismo , Animais , Glicemia/análise , Nitrogênio da Ureia Sanguínea , Reativadores da Colinesterase/sangue , Reativadores da Colinesterase/farmacocinética , Creatina Quinase/sangue , Cães , Glutationa/sangue , Dissulfeto de Glutationa/sangue , Hiperglicemia/sangue , Hiperglicemia/induzido quimicamente , Oximas/sangue , Oximas/farmacocinética , Compostos de Piridínio/sangue , Compostos de Piridínio/farmacocinética , Compostos de Sulfidrila/sangue , Substâncias Reativas com Ácido Tiobarbitúrico/metabolismo , Triglicerídeos/sangueRESUMO
A highly sensitive and selective HPLC-MS/MS method is presented for the quantitative determination of tiloronoxim and its metabolite tilorone in human blood. An aliquot of 200 microl human blood was extracted with a mixture of chloroform/ethyl ether (1/2, v/v), using metoprolol as the internal standard (the IS). Separation was achieved on an Xterra MS C18 column (50 mm x 2.1 mm, 5 microm) with a gradient mobile phase of methanol/water containing 15 mM ammonium bicarbonate (pH 10.5). Detection was performed using positive MRM mode on a TurboIonSpray source. The mass transitions monitored were m/z 426.3-->100.0, m/z 411.3-->100.0 and m/z 268.3-->116.1 for tiloronoxim, tilorone and the IS, respectively. The method was fully validated using total error theory, which is based on beta-expectation tolerance intervals and include trueness and intermediate precision. The method was found to be accurate over a concentration range of 1-100 ng/ml for both compounds. The measurement uncertainty based on beta-expectation tolerance intervals was assessed at each concentration level of the validation standards. This method was successively applied to a pharmacokinetic study of tiloronoxim in healthy volunteers.
Assuntos
Antivirais/sangue , Antivirais/farmacocinética , Cromatografia Líquida de Alta Pressão/métodos , Espectrometria de Massas/métodos , Oximas/sangue , Oximas/farmacocinética , Tilorona/análogos & derivados , Incerteza , Antivirais/administração & dosagem , Estabilidade de Medicamentos , Humanos , Limite de Detecção , Oximas/administração & dosagem , Análise de Regressão , Reprodutibilidade dos Testes , Tilorona/administração & dosagem , Tilorona/sangue , Tilorona/farmacocinética , Fatores de TempoRESUMO
1. The potential of M17055, a novel diuretic candidate, to affect the activities of human CYP enzymes, alter the plasma unbound fraction and compete with concomitant drugs in renal secretion as part of an assessment for drug-drug interactions in metabolism, distribution and excretion was investigated. 2. The effects of M17055 on the activities of human CYP1A2, CYP2E1, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 were considered negligible at clinically relevant concentrations. 3. The majority of M17055 (99%) was bound to human plasma proteins, but it is unlikely to alter the binding of other clinically relevant drugs. 4. The renal clearance of M17055 (corrected for the plasma unbound fraction in male rats) substantially exceeded the glomerular filtration rate and was markedly reduced by treatment with probenecid, suggesting that the renal excretion of M17055 is controlled predominantly by an active secretion mechanism. 5. The results show that M17055 is unlikely to cause or undergo significant pharmacokinetic interactions with concomitant drugs in metabolism and distribution. However, when it is administered simultaneously with certain organic anions, drug-drug interactions during kidney excretion may be possible.